<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03018236</url>
  </required_header>
  <id_info>
    <org_study_id>150488</org_study_id>
    <nct_id>NCT03018236</nct_id>
  </id_info>
  <brief_title>Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial.</brief_title>
  <official_title>The Effect of N-acetylcysteine (NAC) on Treatment of Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Secretaria Nacional de Pol√≠ticas sobre Drogas (SENAD)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the use of N-acetylcysteine in the treatment of alcohol and cocaine use
      disorders. Alcohol users will be split in two groups, one will receive the active
      N-acetylcysteine and the other placebo. The same division will occur with cocaine users. The
      effects of N-acetylcysteine in adherence, abstinence, psychiatric symptoms and stress
      biomarkers will be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      N-acetylcysteine acts replenishing the human body glutathione storages. Glutathione is an
      important antioxidant agent, and also modulates the N-methyl-D-aspartate (NMDA) glutamatergic
      receptor. Glutamate has been associated with the neuroadaptation related to substance use
      disorders, and thus it is considered a potential target for pharmacological interventions
      regarding these disorders. N-acetylcysteine also interacts with the cystine-glutamate
      antiporter on astrocytes hence increasing glutamate release into the extracellular space.

      N-acetylcysteine effects and its implications in the addiction disorders have been studied
      initially with animal models. Glutamate levels normalization through N-acetylcysteine reduced
      compulsive drug self-administration and drug-seeking behavior in mice. In addition, there are
      promising results also with human subjects, showing benefits for cocaine, alcohol and
      cannabis use disorders.

      This study consists of a randomized, double-blind, placebo controlled trial with four arms:
      alcohol users divided into NAC vs Placebo and cocaine users divided into NAC vs Placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who attended all study appointments</measure>
    <time_frame>8 weeks</time_frame>
    <description>Completers (i.e. subjects who attended all study appointments) vs non-completers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Abstinence by urine</measure>
    <time_frame>8 weeks</time_frame>
    <description>Amount of positive urine tests for cocaine users</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abstinence by breathalyzer</measure>
    <time_frame>8 weeks</time_frame>
    <description>Amount of positive breathalyzer tests for alcohol users</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abstinence by self report</measure>
    <time_frame>8 weeks</time_frame>
    <description>Timeline Followback Method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of inpatient treatment</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>The difference (if any) between placebo and intervention groups in the amount of inpatient treatment days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in scores of CGI</measure>
    <time_frame>8 weeks</time_frame>
    <description>Differences in scores of the Clinical Global Impression (CGI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in scores of FAST</measure>
    <time_frame>8 weeks</time_frame>
    <description>Differences in scores of the Functioning Assessment Short Test (FAST).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depressive symptoms</measure>
    <time_frame>8 weeks</time_frame>
    <description>Differences in scores of the Beck Depression Inventory (BDI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety symptoms</measure>
    <time_frame>8 weeks</time_frame>
    <description>Differences in scores of the Beck Anxiety Inventory (BAI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDNF</measure>
    <time_frame>8 weeks</time_frame>
    <description>Differences between groups regarding dosage of Brain Derived Neurotrophic Factor (BDNF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSSG</measure>
    <time_frame>8 weeks</time_frame>
    <description>Differences between groups regarding dosage of Oxidized Glutathione (GSSG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSH</measure>
    <time_frame>8 weeks</time_frame>
    <description>Differences between groups regarding dosage of Glutathione (GSH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GPx</measure>
    <time_frame>8 weeks</time_frame>
    <description>Differences between groups regarding dosage of Glutathione Peroxidase (GPx)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAT</measure>
    <time_frame>8 weeks</time_frame>
    <description>Differences between groups regarding dosage of Catalase (CAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TBARS</measure>
    <time_frame>8 weeks</time_frame>
    <description>Differences between groups regarding dosage of Thiobarbituric Acid Reactive Substances (TBARS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOD</measure>
    <time_frame>8 weeks</time_frame>
    <description>Differences between groups regarding dosage of Superoxide Dismutase (SOD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carbonyl</measure>
    <time_frame>8 weeks</time_frame>
    <description>Differences between groups regarding dosage of Carbonyl</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>8 weeks</time_frame>
    <description>Systematic Assessment for Treatment Emergent Events (SAFTEE) application</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cocaine Addiction</condition>
  <condition>Alcohol Addiction</condition>
  <arm_group>
    <arm_group_label>Alcohol N-acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg N-acetylcysteine capsule by mouth, every 12 hours for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alcohol Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo capsule matching color and smell of the active medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cocaine N-acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg N-acetylcysteine capsule by mouth, every 12 hours for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cocaine Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo capsule matching color and smell of the active medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alcohol N-acetylcysteine</intervention_name>
    <description>1200 mg of NAC per day, taken in two doses, for subjects with alcohol use disorder</description>
    <arm_group_label>Alcohol N-acetylcysteine</arm_group_label>
    <other_name>NAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alcohol Placebo</intervention_name>
    <description>Flour pills looking exactly the same as the active compound, for subjects with alcohol use disorder</description>
    <arm_group_label>Alcohol Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cocaine N-acetylcysteine</intervention_name>
    <description>1200 mg of NAC per day, taken in two doses, for subjects with cocaine use disorder</description>
    <arm_group_label>Cocaine N-acetylcysteine</arm_group_label>
    <other_name>NAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cocaine Placebo</intervention_name>
    <description>Flour pills looking exactly the same as the active compound, for subjects with cocaine use disorder</description>
    <arm_group_label>Cocaine Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnostic of Alcohol or Cocaine Use Disorder

          -  Seven days of inpatient treatment in an addiction treatment specialized unit

        Exclusion Criteria:

          -  Another Substance Use Disorder (exception: tobacco)

          -  Severe medical conditions (cardiac, renal or hepatic), that preclude subject
             participation

          -  History of asthma or convulsions medication use

          -  Recent use (&lt;14 days) of any medication that could interfere with the study medication

          -  History of anaphylactic reactions with the study medication

          -  Suicide risk

          -  Inability to understand the informed consent form or to comply with the study
             requirements

          -  Any severe neuropsychiatric condition, not caused by the substance use, that requires
             specific medication treatments and could interfere with the study development, in the
             investigators opinion (for instance: dementia, schizophrenia or other psychoses,
             multiple sclerosis, severe depression, stroke, epilepsy, bipolar disorder)

          -  Failing to complete the screening procedures prior to the study first week
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisia von Diemen, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of Rio Grande do Sul (UFRGS)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Flavio Pechansky, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Rio Grande do Sul (UFRGS)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisia von Diemen, PhD</last_name>
    <phone>+55 51 3359 6471</phone>
    <email>lisiavd@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thiago C Hartmann, MsC</last_name>
    <phone>+55 51 3359 6476</phone>
    <email>hartmann321@yahoo.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre - Unidade Alvaro Alvim</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90420-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thiago C Hartmann, MsC</last_name>
      <phone>+55 51 3359 6476</phone>
      <email>hartmann321@yahoo.com.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Agrawal A, Verweij KJ, Gillespie NA, Heath AC, Lessov-Schlaggar CN, Martin NG, Nelson EC, Slutske WS, Whitfield JB, Lynskey MT. The genetics of addiction-a translational perspective. Transl Psychiatry. 2012 Jul 17;2:e140. doi: 10.1038/tp.2012.54. Review. Erratum in: Transl Psychiatry. 2012;2:e193.</citation>
    <PMID>22806211</PMID>
  </reference>
  <reference>
    <citation>Andreazza AC, Frey BN, Valvassori SS, Zanotto C, Gomes KM, Comim CM, Cassini C, Stertz L, Ribeiro LC, Quevedo J, Kapczinski F, Berk M, Gon√ßalves CA. DNA damage in rats after treatment with methylphenidate. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Aug 15;31(6):1282-8. Epub 2007 Jun 2.</citation>
    <PMID>17614179</PMID>
  </reference>
  <reference>
    <citation>Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Altieri A, Cogliano V; WHO International Agency for Research on Cancer Monograph Working Group. Carcinogenicity of alcoholic beverages. Lancet Oncol. 2007 Apr;8(4):292-3.</citation>
    <PMID>17431955</PMID>
  </reference>
  <reference>
    <citation>Baker DA, McFarland K, Lake RW, Shen H, Toda S, Kalivas PW. N-acetyl cysteine-induced blockade of cocaine-induced reinstatement. Ann N Y Acad Sci. 2003 Nov;1003:349-51.</citation>
    <PMID>14684458</PMID>
  </reference>
  <reference>
    <citation>Berk M, Malhi GS, Gray LJ, Dean OM. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci. 2013 Mar;34(3):167-77. doi: 10.1016/j.tips.2013.01.001. Epub 2013 Jan 29. Review.</citation>
    <PMID>23369637</PMID>
  </reference>
  <reference>
    <citation>Bibel M, Barde YA. Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev. 2000 Dec 1;14(23):2919-37. Review.</citation>
    <PMID>11114882</PMID>
  </reference>
  <reference>
    <citation>Calado RT, Young NS. Telomere diseases. N Engl J Med. 2009 Dec 10;361(24):2353-65. doi: 10.1056/NEJMra0903373. Review.</citation>
    <PMID>20007561</PMID>
  </reference>
  <reference>
    <citation>Chen CH, Pan CH, Chen CC, Huang MC. Increased oxidative DNA damage in patients with alcohol dependence and its correlation with alcohol withdrawal severity. Alcohol Clin Exp Res. 2011 Feb;35(2):338-44. doi: 10.1111/j.1530-0277.2010.01349.x. Epub 2010 Nov 10.</citation>
    <PMID>21070251</PMID>
  </reference>
  <reference>
    <citation>Corominas-Roso M, Roncero C, Daigre C, Grau-Lopez L, Ros-Cucurull E, Rodr√≠guez-Cintas L, Sanchez-Mora C, Lopez MV, Ribases M, Casas M. Changes in brain-derived neurotrophic factor (BDNF) during abstinence could be associated with relapse in cocaine-dependent patients. Psychiatry Res. 2015 Feb 28;225(3):309-14. doi: 10.1016/j.psychres.2014.12.019. Epub 2014 Dec 20.</citation>
    <PMID>25592977</PMID>
  </reference>
  <reference>
    <citation>Costa MA, Girard M, Dalmay F, Malauzat D. Brain-derived neurotrophic factor serum levels in alcohol-dependent subjects 6 months after alcohol withdrawal. Alcohol Clin Exp Res. 2011 Nov;35(11):1966-73. doi: 10.1111/j.1530-0277.2011.01548.x. Epub 2011 Aug 16.</citation>
    <PMID>21848960</PMID>
  </reference>
  <reference>
    <citation>Cross CE, Valacchi G, Schock B, Wilson M, Weber S, Eiserich J, van der Vliet A. Environmental oxidant pollutant effects on biologic systems: a focus on micronutrient antioxidant-oxidant interactions. Am J Respir Crit Care Med. 2002 Dec 15;166(12 Pt 2):S44-50. Review.</citation>
    <PMID>12471088</PMID>
  </reference>
  <reference>
    <citation>Davis MI. Ethanol-BDNF interactions: still more questions than answers. Pharmacol Ther. 2008 Apr;118(1):36-57. doi: 10.1016/j.pharmthera.2008.01.003. Epub 2008 Feb 2. Review.</citation>
    <PMID>18394710</PMID>
  </reference>
  <reference>
    <citation>Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci. 2011 Mar;36(2):78-86. doi: 10.1503/jpn.100057. Review.</citation>
    <PMID>21118657</PMID>
  </reference>
  <reference>
    <citation>Degenhardt L, Singleton J, Calabria B, McLaren J, Kerr T, Mehta S, Kirk G, Hall WD. Mortality among cocaine users: a systematic review of cohort studies. Drug Alcohol Depend. 2011 Jan 15;113(2-3):88-95. doi: 10.1016/j.drugalcdep.2010.07.026. Epub 2010 Sep 15. Review.</citation>
    <PMID>20828942</PMID>
  </reference>
  <reference>
    <citation>Ersche KD, Jones PS, Williams GB, Robbins TW, Bullmore ET. Cocaine dependence: a fast-track for brain ageing? Mol Psychiatry. 2013 Feb;18(2):134-5. doi: 10.1038/mp.2012.31. Epub 2012 Apr 24.</citation>
    <PMID>22525488</PMID>
  </reference>
  <reference>
    <citation>Frey BN, Valvassori SS, Gomes KM, Martins MR, Dal-Pizzol F, Kapczinski F, Quevedo J. Increased oxidative stress in submitochondrial particles after chronic amphetamine exposure. Brain Res. 2006 Jun 30;1097(1):224-9. Epub 2006 May 30.</citation>
    <PMID>16730669</PMID>
  </reference>
  <reference>
    <citation>Garbutt JC, Greenblatt AM, West SL, Morgan LC, Kampov-Polevoy A, Jordan HS, Bobashev GV. Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence. Addiction. 2014 Aug;109(8):1274-84. doi: 10.1111/add.12557. Epub 2014 May 23. Review.</citation>
    <PMID>24661324</PMID>
  </reference>
  <reference>
    <citation>Grant JE, Odlaug BL, Kim SW. A double-blind, placebo-controlled study of N-acetyl cysteine plus naltrexone for methamphetamine dependence. Eur Neuropsychopharmacol. 2010 Nov;20(11):823-8. doi: 10.1016/j.euroneuro.2010.06.018. Epub 2010 Jul 22.</citation>
    <PMID>20655182</PMID>
  </reference>
  <reference>
    <citation>Gray KM, Carpenter MJ, Baker NL, DeSantis SM, Kryway E, Hartwell KJ, McRae-Clark AL, Brady KT. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry. 2012 Aug;169(8):805-12. doi: 10.1176/appi.ajp.2012.12010055. Erratum in: Am J Psychiatry. 2012 Aug 1;169(8):869.</citation>
    <PMID>22706327</PMID>
  </reference>
  <reference>
    <citation>Gray KM, Watson NL, Carpenter MJ, Larowe SD. N-acetylcysteine (NAC) in young marijuana users: an open-label pilot study. Am J Addict. 2010 Mar-Apr;19(2):187-9. doi: 10.1111/j.1521-0391.2009.00027.x.</citation>
    <PMID>20163391</PMID>
  </reference>
  <reference>
    <citation>Griffith JD, Rowan-Szal GA, Roark RR, Simpson DD. Contingency management in outpatient methadone treatment: a meta-analysis. Drug Alcohol Depend. 2000 Feb 1;58(1-2):55-66.</citation>
    <PMID>10669055</PMID>
  </reference>
  <reference>
    <citation>Haile CN, Kosten TR, Kosten TA. Genetics of dopamine and its contribution to cocaine addiction. Behav Genet. 2007 Jan;37(1):119-45. Epub 2006 Oct 25. Review.</citation>
    <PMID>17063402</PMID>
  </reference>
  <reference>
    <citation>Huang MC, Chen CC, Peng FC, Tang SH, Chen CH. The correlation between early alcohol withdrawal severity and oxidative stress in patients with alcohol dependence. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Feb 1;33(1):66-9. doi: 10.1016/j.pnpbp.2008.10.009. Epub 2008 Oct 27.</citation>
    <PMID>18996163</PMID>
  </reference>
  <reference>
    <citation>Huang MC, Chen CH, Liu HC, Chen CC, Ho CC, Leu SJ. Differential patterns of serum brain-derived neurotrophic factor levels in alcoholic patients with and without delirium tremens during acute withdrawal. Alcohol Clin Exp Res. 2011 Jan;35(1):126-31. doi: 10.1111/j.1530-0277.2010.01329.x. Epub 2010 Oct 6.</citation>
    <PMID>21039634</PMID>
  </reference>
  <reference>
    <citation>Huang MC, Chen CH, Chen CH, Liu SC, Ho CJ, Shen WW, Leu SJ. Alterations of serum brain-derived neurotrophic factor levels in early alcohol withdrawal. Alcohol Alcohol. 2008 May-Jun;43(3):241-5. doi: 10.1093/alcalc/agm172. Epub 2008 Mar 7.</citation>
    <PMID>18326550</PMID>
  </reference>
  <reference>
    <citation>Jaffe JH. Trivializing dependence. Br J Addict. 1990 Nov;85(11):1425-7; discussion 1429-31.</citation>
    <PMID>2285838</PMID>
  </reference>
  <reference>
    <citation>Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, Kim MM, Shanahan E, Gass CE, Rowe CJ, Garbutt JC. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014 May 14;311(18):1889-900. doi: 10.1001/jama.2014.3628. Review.</citation>
    <PMID>24825644</PMID>
  </reference>
  <reference>
    <citation>Kampman KM, Volpicelli JR, McGinnis DE, Alterman AI, Weinrieb RM, D'Angelo L, Epperson LE. Reliability and validity of the Cocaine Selective Severity Assessment. Addict Behav. 1998 Jul-Aug;23(4):449-61.</citation>
    <PMID>9698974</PMID>
  </reference>
  <reference>
    <citation>Kendler KS, Ohlsson H, Maes HH, Sundquist K, Lichtenstein P, Sundquist J. A population-based Swedish Twin and Sibling Study of cannabis, stimulant and sedative abuse in men. Drug Alcohol Depend. 2015 Apr 1;149:49-54. doi: 10.1016/j.drugalcdep.2015.01.016. Epub 2015 Jan 28.</citation>
    <PMID>25660314</PMID>
  </reference>
  <reference>
    <citation>Kenward MG. Selection models for repeated measurements with non-random dropout: an illustration of sensitivity. Stat Med. 1998 Dec 15;17(23):2723-32.</citation>
    <PMID>9881418</PMID>
  </reference>
  <reference>
    <citation>Kessler F, Cacciola J, Alterman A, Faller S, Souza-Formigoni ML, Cruz MS, Brasiliano S, Pechansky F. Psychometric properties of the sixth version of the Addiction Severity Index (ASI-6) in Brazil. Rev Bras Psiquiatr. 2012 Mar;34(1):24-33.</citation>
    <PMID>22392385</PMID>
  </reference>
  <reference>
    <citation>Laird NM. Missing data in longitudinal studies. Stat Med. 1988 Jan-Feb;7(1-2):305-15.</citation>
    <PMID>3353609</PMID>
  </reference>
  <reference>
    <citation>LaRowe SD, Mardikian P, Malcolm R, Myrick H, Kalivas P, McFarland K, Saladin M, McRae A, Brady K. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict. 2006 Jan-Feb;15(1):105-10.</citation>
    <PMID>16449100</PMID>
  </reference>
  <reference>
    <citation>LaRowe SD, Myrick H, Hedden S, Mardikian P, Saladin M, McRae A, Brady K, Kalivas PW, Malcolm R. Is cocaine desire reduced by N-acetylcysteine? Am J Psychiatry. 2007 Jul;164(7):1115-7.</citation>
    <PMID>17606664</PMID>
  </reference>
  <reference>
    <citation>Lussier JP, Heil SH, Mongeon JA, Badger GJ, Higgins ST. A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction. 2006 Feb;101(2):192-203. Review.</citation>
    <PMID>16445548</PMID>
  </reference>
  <reference>
    <citation>Lynskey MT, Agrawal A, Henders A, Nelson EC, Madden PA, Martin NG. An Australian twin study of cannabis and other illicit drug use and misuse, and other psychopathology. Twin Res Hum Genet. 2012 Oct;15(5):631-41. doi: 10.1017/thg.2012.41. Epub 2012 Jul 9.</citation>
    <PMID>22874079</PMID>
  </reference>
  <reference>
    <citation>Mardikian PN, LaRowe SD, Hedden S, Kalivas PW, Malcolm RJ. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):389-94. Epub 2006 Nov 17.</citation>
    <PMID>17113207</PMID>
  </reference>
  <reference>
    <citation>McGinty JF, Mendelson JE. Is brain-derived neurotrophic factor a selective biomarker that predicts cocaine relapse outcomes? Biol Psychiatry. 2011 Oct 15;70(8):700-1. doi: 10.1016/j.biopsych.2011.08.017.</citation>
    <PMID>21967984</PMID>
  </reference>
  <reference>
    <citation>McGinty JF, Whitfield TW Jr, Berglind WJ. Brain-derived neurotrophic factor and cocaine addiction. Brain Res. 2010 Feb 16;1314:183-93. doi: 10.1016/j.brainres.2009.08.078. Epub 2009 Sep 2. Review.</citation>
    <PMID>19732758</PMID>
  </reference>
  <reference>
    <citation>McLellan AT, Alterman AI, Cacciola J, Metzger D, O'Brien CP. A new measure of substance abuse treatment. Initial studies of the treatment services review. J Nerv Ment Dis. 1992 Feb;180(2):101-10.</citation>
    <PMID>1737971</PMID>
  </reference>
  <reference>
    <citation>McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9(3):199-213.</citation>
    <PMID>1334156</PMID>
  </reference>
  <reference>
    <citation>Nestler EJ. From neurobiology to treatment: progress against addiction. Nat Neurosci. 2002 Nov;5 Suppl:1076-9. Review.</citation>
    <PMID>12403990</PMID>
  </reference>
  <reference>
    <citation>Nestler EJ. The neurobiology of cocaine addiction. Sci Pract Perspect. 2005 Dec;3(1):4-10. Review.</citation>
    <PMID>18552739</PMID>
  </reference>
  <reference>
    <citation>Olive MF, Cleva RM, Kalivas PW, Malcolm RJ. Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacol Biochem Behav. 2012 Feb;100(4):801-10. doi: 10.1016/j.pbb.2011.04.015. Epub 2011 Apr 22. Review.</citation>
    <PMID>21536062</PMID>
  </reference>
  <reference>
    <citation>de Lima Os√≥rio F, Crippa JA, Loureiro SR. Further psychometric study of the Beck Anxiety Inventory including factorial analysis and social anxiety disorder screening. Int J Psychiatry Clin Pract. 2011 Nov;15(4):255-62. doi: 10.3109/13651501.2011.605955.</citation>
    <PMID>22121998</PMID>
  </reference>
  <reference>
    <citation>Patriquin MA, Bauer IE, Soares JC, Graham DP, Nielsen DA. Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system. Psychiatr Genet. 2015 Oct;25(5):181-93. doi: 10.1097/YPG.0000000000000095. Review.</citation>
    <PMID>26146874</PMID>
  </reference>
  <reference>
    <citation>Pavanello S, Hoxha M, Dioni L, Bertazzi PA, Snenghi R, Nalesso A, Ferrara SD, Montisci M, Baccarelli A. Shortened telomeres in individuals with abuse in alcohol consumption. Int J Cancer. 2011 Aug 15;129(4):983-92. doi: 10.1002/ijc.25999. Epub 2011 Apr 25.</citation>
    <PMID>21351086</PMID>
  </reference>
  <reference>
    <citation>Prendergast M, Podus D, Finney J, Greenwell L, Roll J. Contingency management for treatment of substance use disorders: a meta-analysis. Addiction. 2006 Nov;101(11):1546-60. Review.</citation>
    <PMID>17034434</PMID>
  </reference>
  <reference>
    <citation>Rabkin JG, Markowitz JS, Ocepek-Welikson K, Wager SS. General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. J Clin Psychopharmacol. 1992 Feb;12(1):3-10.</citation>
    <PMID>1552037</PMID>
  </reference>
  <reference>
    <citation>Rosa AR, S√°nchez-Moreno J, Mart√≠nez-Aran A, Salamero M, Torrent C, Reinares M, Comes M, Colom F, Van Riel W, Ayuso-Mateos JL, Kapczinski F, Vieta E. Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clin Pract Epidemiol Ment Health. 2007 Jun 7;3:5.</citation>
    <PMID>17555558</PMID>
  </reference>
  <reference>
    <citation>Sansone RA, Sansone LA. Getting a Knack for NAC: N-Acetyl-Cysteine. Innov Clin Neurosci. 2011 Jan;8(1):10-4.</citation>
    <PMID>21311702</PMID>
  </reference>
  <reference>
    <citation>Santos Cruz M, Andrade T, Bastos FI, Leal E, Bertoni N, Villar LM, Tiesmaki M, Fischer B. Key drug use, health and socio-economic characteristics of young crack users in two Brazilian cities. Int J Drug Policy. 2013 Sep;24(5):432-8. doi: 10.1016/j.drugpo.2013.03.012. Epub 2013 Apr 28.</citation>
    <PMID>23632130</PMID>
  </reference>
  <reference>
    <citation>Schmaal L, Berk L, Hulstijn KP, Cousijn J, Wiers RW, van den Brink W. Efficacy of N-acetylcysteine in the treatment of nicotine dependence: a double-blind placebo-controlled pilot study. Eur Addict Res. 2011;17(4):211-6. doi: 10.1159/000327682. Epub 2011 May 24.</citation>
    <PMID>21606648</PMID>
  </reference>
  <reference>
    <citation>Schmaal L, Veltman DJ, Nederveen A, van den Brink W, Goudriaan AE. N-acetylcysteine normalizes glutamate levels in cocaine-dependent patients: a randomized crossover magnetic resonance spectroscopy study. Neuropsychopharmacology. 2012 Aug;37(9):2143-52. doi: 10.1038/npp.2012.66. Epub 2012 May 2.</citation>
    <PMID>22549117</PMID>
  </reference>
  <reference>
    <citation>Schneider R Jr, Santos CF, Clarimundo V, Dalmaz C, Elisabetsky E, Gomez R. N-acetylcysteine prevents behavioral and biochemical changes induced by alcohol cessation in rats. Alcohol. 2015 May;49(3):259-63. doi: 10.1016/j.alcohol.2015.01.009. Epub 2015 Feb 13.</citation>
    <PMID>25771148</PMID>
  </reference>
  <reference>
    <citation>Shen Q, Zhao X, Yu L, Zhang Z, Zhou D, Kan M, Zhang D, Cao L, Xing Q, Yang Y, Xu H, He L, Liu Y. Association of leukocyte telomere length with type 2 diabetes in mainland Chinese populations. J Clin Endocrinol Metab. 2012 Apr;97(4):1371-4. doi: 10.1210/jc.2011-1562. Epub 2012 Feb 8.</citation>
    <PMID>22319045</PMID>
  </reference>
  <reference>
    <citation>Sinha R. New findings on biological factors predicting addiction relapse vulnerability. Curr Psychiatry Rep. 2011 Oct;13(5):398-405. doi: 10.1007/s11920-011-0224-0. Review.</citation>
    <PMID>21792580</PMID>
  </reference>
  <reference>
    <citation>Skinner MD, Lahmek P, Pham H, Aubin HJ. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One. 2014 Feb 10;9(2):e87366. doi: 10.1371/journal.pone.0087366. eCollection 2014.</citation>
    <PMID>24520330</PMID>
  </reference>
  <reference>
    <citation>Sordi AO, Pechansky F, Kessler FH, Kapczinski F, Pfaffenseller B, Gubert C, de Aguiar BW, de Magalh√£es Narvaez JC, Ornell F, von Diemen L. Oxidative stress and BDNF as possible markers for the severity of crack cocaine use in early withdrawal. Psychopharmacology (Berl). 2014 Oct;231(20):4031-9. doi: 10.1007/s00213-014-3542-1. Epub 2014 Mar 28.</citation>
    <PMID>24676990</PMID>
  </reference>
  <reference>
    <citation>Spencer RL, Hutchison KE. Alcohol, aging, and the stress response. Alcohol Res Health. 1999;23(4):272-83.</citation>
    <PMID>10890824</PMID>
  </reference>
  <reference>
    <citation>Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 1989 Nov;84(11):1353-7.</citation>
    <PMID>2597811</PMID>
  </reference>
  <reference>
    <citation>Urbanska EM, Czuczwar SJ, Kleinrok Z, Turski WA. Excitatory amino acids in epilepsy. Restor Neurol Neurosci. 1998;13(1-2):25-39.</citation>
    <PMID>12671285</PMID>
  </reference>
  <reference>
    <citation>Verdejo-Garc√≠a A, P√©rez-Garc√≠a M. Profile of executive deficits in cocaine and heroin polysubstance users: common and differential effects on separate executive components. Psychopharmacology (Berl). 2007 Mar;190(4):517-30. Epub 2006 Nov 29.</citation>
    <PMID>17136401</PMID>
  </reference>
  <reference>
    <citation>Volkow ND, Koob G, Baler R. Biomarkers in substance use disorders. ACS Chem Neurosci. 2015 Apr 15;6(4):522-5. doi: 10.1021/acschemneuro.5b00067. Epub 2015 Mar 18. Review.</citation>
    <PMID>25734247</PMID>
  </reference>
  <reference>
    <citation>von Diemen L, Kapczinski F, Sordi AO, de Magalh√£es Narvaez JC, Guimar√£es LS, Kessler FH, Pfaffenseller B, de Aguiar BW, de Moura Gubert C, Pechansky F. Increase in brain-derived neurotrophic factor expression in early crack cocaine withdrawal. Int J Neuropsychopharmacol. 2014 Jan;17(1):33-40. doi: 10.1017/S146114571300103X. Epub 2013 Sep 26.</citation>
    <PMID>24067327</PMID>
  </reference>
  <reference>
    <citation>Walker J, Winhusen T, Storkson JM, Lewis D, Pariza MW, Somoza E, Somoza V. Total antioxidant capacity is significantly lower in cocaine-dependent and methamphetamine-dependent patients relative to normal controls: results from a preliminary study. Hum Psychopharmacol. 2014 Nov;29(6):537-43.</citation>
    <PMID>25087849</PMID>
  </reference>
  <reference>
    <citation>Wei LJ, Lachin JM. Properties of the urn randomization in clinical trials. Control Clin Trials. 1988 Dec;9(4):345-64. Erratum in: Controlled Clin Trials 1989 Mar;10(1):following 126.</citation>
    <PMID>3203525</PMID>
  </reference>
  <reference>
    <citation>Wu Y, Pan X, Zhang S, Wang W, Cai M, Li Y, Yang F, Guo H. Protective effect of corn peptides against alcoholic liver injury in men with chronic alcohol consumption: a randomized double-blind placebo-controlled study. Lipids Health Dis. 2014 Dec 13;13:192. doi: 10.1186/1476-511X-13-192.</citation>
    <PMID>25494594</PMID>
  </reference>
  <reference>
    <citation>Yang Z, Ye J, Li C, Zhou D, Shen Q, Wu J, Cao L, Wang T, Cui D, He S, Qi G, He L, Liu Y. Drug addiction is associated with leukocyte telomere length. Sci Rep. 2013;3:1542. doi: 10.1038/srep01542.</citation>
    <PMID>23528991</PMID>
  </reference>
  <reference>
    <citation>Zaparte A, Viola TW, Grassi-Oliveira R, da Silva Morrone M, Moreira JC, Bauer ME. Early abstinence of crack-cocaine is effective to attenuate oxidative stress and to improve antioxidant defences. Psychopharmacology (Berl). 2015 Apr;232(8):1405-13. doi: 10.1007/s00213-014-3779-8. Epub 2014 Oct 23.</citation>
    <PMID>25338778</PMID>
  </reference>
  <reference>
    <citation>Zhou W, Kalivas PW. N-acetylcysteine reduces extinction responding and induces enduring reductions in cue- and heroin-induced drug-seeking. Biol Psychiatry. 2008 Feb 1;63(3):338-40. Epub 2007 Aug 24.</citation>
    <PMID>17719565</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2017</study_first_submitted>
  <study_first_submitted_qc>January 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2017</study_first_posted>
  <last_update_submitted>January 20, 2017</last_update_submitted>
  <last_update_submitted_qc>January 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cocaine</keyword>
  <keyword>alcohol</keyword>
  <keyword>substance use disorders</keyword>
  <keyword>addiction</keyword>
  <keyword>N-acetylcysteine</keyword>
  <keyword>randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behavior, Addictive</mesh_term>
    <mesh_term>Cocaine-Related Disorders</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

